Market Development Leader
Revvity Health Sciences, Inc.
I hold a Biochemistry Honours Degree from Glasgow University followed by a PhD in Cancer biology from Beatson Institute for Cancer Research.
The next 5 years were spent honing my research and assay development techniques at British Biotech, Axis Shield and AstraZeneca before joining the commercial world in 2001. Since 2009 I have had the pleasure of working with the Celigo image cytometer technology at Nexcelom and it continues development within the Perkin Elmer and now Revvity family. From 2018 to 2022, I headed up the Nexcelom business in EMEAI. 2023 saw a new challenge with the complete integration of Nexcelom into Perkin Elmer and the transformation of our new company into Revvity. My current role is the Market Development Leader for the Cellular imaging portfolio, which contains the legacy Nexcelom cell counting and imaging systems as well as legacy Perkin Elmer high content systems